Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Troels Torben Marstrand
  • Rehannah Borup
  • A Willer
  • N Borregaard
  • Albin Gustav Sandelin
  • B T Porse
  • K Theilgaard-Mönch
View graph of relations
Chromosomal translocations of transcription factors generating fusion proteins with aberrant transcriptional activity are common in acute leukemia. In acute promyelocytic leukemia (APL), the promyelocytic leukemia-retinoic-acid receptor alpha (PML-RARA) fusion protein, which emerges as a consequence of the t(15;17) translocation, acts as a transcriptional repressor that blocks neutrophil differentiation at the promyelocyte (PM) stage. In this study, we used publicly available microarray data sets and identified signatures of genes dysregulated in APL by comparison of gene expression profiles of APL cells and normal PMs representing the same stage of differentiation. We next subjected our identified APL signatures of dysregulated genes to a series of computational analyses leading to (i) the finding that APL cells show stem cell properties with respect to gene expression and transcriptional regulation, and (ii) the identification of candidate drugs and drug targets for therapeutic interventions. Significantly, our study provides a conceptual framework that can be applied to any subtype of AML and cancer in general to uncover novel information from published microarray data sets at low cost. In a broader perspective, our study provides strong evidence that genomic strategies might be used in a clinical setting to prospectively identify candidate drugs that subsequently are validated in vitro to define the most effective drug combination for individual cancer patients on a rational basis.
Original languageEnglish
JournalLeukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Volume24
Issue number7
Pages (from-to)1265-75
Number of pages11
DOIs
Publication statusPublished - 1 Jul 2010

ID: 32226022